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17 Abstract 
18 The cytochrome bc1 complex is a key component of the mitochondrial respiratory chains of many 
19 eukaryotic microorganisms that are pathogenic for plants or humans, such as fungi responsible for 
20 crop diseases and Plasmodium falciparum, which causes human malaria. Cytochrome bc1 is an 
21 enzyme that contains two (ubi)quinone/quinol binding sites, which can be exploited for the 
22 development of fungicidal and chemotherapeutic agents. Here we review recent progress in 
23 determination of the structure and mechanism of action of cytochrome bc1, and the associated 
24 development of antimicrobial agents (and associated resistance mechanisms) targeting its activity. 
25
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29 Abbreviations
30 Δp - protonmotive force
31 AOX - (mitochondrial) alternative oxidase
32 cyt - cytochrome
33 DHODH - dihydroorotate dehydrogenase
34 Em,7  - (redox) midpoint potential at pH 7
35 ED - extrinsic domain
36 EPR - electron paramagnetic resonance 
37 FRAC - Fungicide Resistance Action Committee
38 HHDBT - n-heptyl-6-hydroxy-4,7-dioxobenzothiazole
39 IMM - inner mitochondrial membrane
40 IMS - (mitochondrial) intermembrane space
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41 ISP - (Rieske) iron-sulphur protein
42 NQNO - n-nonyl quinoline N-oxide 
43 MDR - multiple drug resistance
44 MOA - methoxyacrylate
45 mtDNA - mitochondrial DNA
46 Qi - site of (ubi)quinone reduction within cytochrome b
47 QiI - Qi site inhibitor
48 Qo - site of (ubi)quinol oxidation within cytochrome b
49 QoI - Qo site inhibitor
50 ROS - reactive oxygen species
51 SAR - structure activity relationship
52 SHAM - salicylhydroxamic acid
53 SQi - semiquinone bound at the Qi site of cytochrome b
54 SQo - semiquinone bound at the Qo site of cytochrome b
55 UHDBT - n-undecyl hydroxy dibenzothiazole
56
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57 Introduction and general enzymatic mechanism of the cytochrome bc1 complex
58 The cytochrome bc1 complex (respiratory Complex III, Cyt bc1, EC: 1.10.2.2) of eukaryotic 
59 mitochondrial- and prokaryotic energy transducing membranes is a proven target for antimicrobial 
60 agents of medical and agricultural interest [1-7].  This enzyme, which is widespread in nature, 
61 functions as a protonmotive ubiquinol:cytochrome c oxidoreductase, conserving- and converting 
62 the Gibbs energy obtained from the exergonic oxidation of ubiquinol by cytochrome c into a 
63 transmembrane proton gradient which may be harnessed for other endergonic processes, typically 
64 ATP synthesis by an FoF1 ATP synthase [8-9] .
65 Cyt bc1 is a multimeric, homodimeric complex. In eukaroytes (the focus of this review), the 
66 monomer consists of 10-11 discrete polypeptides, with a molecular mass of approximately 240 
67 kDa [8,10]. All subunits are nuclearly encoded with the exception of cytochrome b (cyt b), which 
68 is encoded by the mitochondrial genome. Three subunits - cyt b, the Rieske [2Fe2S] iron-sulphur 
69 protein (ISP) and cytochrome c1 (cyt c1) form the highly conserved electron- and proton 
70 transferring catalytic engine of the enzyme (Fig. 1), embedded within the inner mitochondrial 
71 membrane (IMM). The [2Fe2S] cluster and haem group of cyt c1 form the 'high potential' chain of 
72 cyt bc1, with midpoint redox potentials (Em,7) of approximately +280 and +240 mV respectively. 
73 The cytochrome b polypeptide forms the 'low potential' transmembrane electron transfer pathway 
74 and binds two b-type haems, designated bL and bH, with Em,7 values of approximately -100 and 
75 +50 mV respectively. (For reference, the Em,7 for the 2 electron redox chemistry of the 
76 ubiquinone/ubiquinol redox couple is approximately + 60 mV). During the catalytic cycle, which 
77 is described in more detail below, cyt bc1 oxidises two molecules of ubiquinol in a stepwise manner, 
78 reducing two molecules of the soluble acceptor cytochrome c and one molecule of ubiquinone. 
79 The protonmotive activity inherent to this catalytic cycle results in the deposition of four protons 
80 against the electrochemical gradient into the intermembrane space, per two electrons transferred 
81 to cyt c, with the concomitant uptake of two protons from the mitochondrial matrix [9,11,12].  
82
83 The ubiquinol- and ubiquinone binding sites of cyt bc1 are termed Qo and Qi, for the sites of 
84 (ubi)quinol oxidation and (ubi)quinone reduction, respectively. They form exploitable targets for 
85 competitive inhibitors and are located within cyt b, disposed on opposite sides of the IMM and 
86 linked by haems bL and bH.  The bifurcating electron-transfer chemistry between the high- and low 
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87 potential chains of cyt bc1 is highly unusual, and best understood through the framework of the Q-
88 cycle model (Fig. 2), originally proposed by Peter Mitchell in 1975 and substantially developed 
89 by others since [13-18].  The basic tenets of the model are this.  A ubiquinol molecule binds at the 
90 quinol oxidation (Qo) site of cyt b, located towards the intermembrane space (i.e. electrochemically 
91 positive)-side of the IMM. This ubiquinol serves as a one-electron reductant for the [2Fe2S] cluster 
92 of the mobile extrinsic domain of the ISP (the ISP-ED), the entry point for the high potential chain 
93 within bc1. The ISP-ED effectively acts as a tethered substrate and kinetic gate facilitating electron 
94 bifurcation, although it is important to note that this in itself is not the only factor controlling the 
95 bifurcation reaction [19-22]. This electron transfer reaction from ubiquinol to the ISP-ED (which 
96 is rate-limiting for the chemistry at Qo) generates a strongly-reducing semiquinone (SQo) radical 
97 at Qo. The reactivity of SQo must be carefully controlled to minimise energetically wasteful (and 
98 potentially harmful) side reactions with molecular oxygen. The mechanisms by which this radical 
99 intermediate - an elusive species - is managed at Qo are subject to much investigation, discussion 
100 of which is beyond the scope of this review, but the interested reader is referred to [23-26] for 
101 further details. Protons released from ubiquinol oxidation at Qo are deposited into the 
102 intermembrane space (IMS) bulk phase. SQo is of sufficiently negative redox potential (c. -160 
103 mV) to reduce the low potential chain within cyt b, with electron entry at haem bL, which is then 
104 rapidly oxidised by haem bH, the electron donor to Qi-bound ubiquinone. This one electron transfer 
105 reaction creates a tightly bound (and relatively stable) semiquinone species at Qi (SQi), which is 
106 reduced to ubiquinol by a second turnover of the Qo site and uptake of two protons from the 
107 mitochondrial matrix, and the cycle is complete. The tight binding of SQi at Qi ensures that the 
108 thermodynamics are favourable for the first one-electron transfer reaction to substrate ubiquinone 
109 at this site, which otherwise would be energetically uphill [9]. 
110
111 Structure, function and inhibition of the cyt bc1 Qo- and Qi sites
112 High resolution (< 3.0 Å) atomic structures of cyt bc1 co-crystallised with a variety of Qo/Qi site 
113 occupants are available for the chicken, bovine, yeast (Saccharomyces cerevisiae) and bacterial 
114 (Rhodobacter sphaeroides, R. capsulatus and Paracoccus denitrificans) enzymes (see survey in 
115 [10]). Recently, single particle cryo-electron microscopy has proven to be useful tool for structural 
116 investigation of this enzyme [27]. No crystal structures of cyt bc1 are available from human- or 
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117 plant pathogen sources, however the yeast enzyme has proved a useful and genetically amenable 
118 model in many instances [1,4,28-32]. 
119 The Qo site within cyt b is composed from components encompassing the C-terminal domain of 
120 transmembrane helix C, surface helix cd1 and the region encompassing the "PEWY" (Pro271-Glu-
121 Trp-Tyr274, yeast notation) loop/ef helix to transmembrane helix F1 (Fig. 3). It forms a large, 
122 bifurcated, and predominantly hydrophobic volume [33,34].  Cyt bc1 has been co-crystallised with 
123 a variety of competitive inhibitors for the Qo site (see [10,34] and references therein, also [4]), but, 
124 despite extensive efforts, there are no atomic structures available for the enzyme with substrate 
125 ubiquinol bound at Qo.  Ligands binding within Qo may be broadly classified as 'bL distal' or 'bL 
126 proximal' species depending on their positioning within the site with respect to haem bL. bL distal 
127 inhibitors, such as stigmatellin, n-nonyl quinoline N-oxide (NQNO), n-undecyl hydroxy 
128 dibenzothiazole (UHDBT) and atovaquone bind in a region of Qo in close proximity to the ISP 
129 (Fig. 1), often forming a strong hydrogen bond to a histidine ligand (H181) of the [2Fe2S] cluster, 
130 and restricting the movement of the ISP-ED in crystallographic studies [10,19,34].  As such, this 
131 class of inhibitor may also be classified as 'Pf' ('P' referring to Qp, an alternative nomenclature for 
132 Qo (i.e. the positive side of the energy coupling membrane), with 'f' indicating that the ISP-ED is 
133 fixed in position) [34]. These inhibitors may also alter the redox- and EPR spectroscopic properties 
134 of the [2Fe2S] cluster, a clue to their mode of action prior to the elucidation of the atomic structure 
135 of cyt bc1. To complicate matters, it should be noted that not all bL-distal/Pf inhibitors form H-
136 bonding associations with the ISP-ED. Famoxadone (an oxazolidine-dione-containing synthetic 
137 fungicide) is a useful case-in-point here, demonstrating direct Qo ligand/ISP-ED interactions are 
138 in themselves insufficient to retard the movement of the ISP-ED, and may arise from ligand-
139 induced perturbation of the protein fold around this region of cyt b [35]. bL-distal inhibitors may 
140 also form hydrogen-bonding interactions with the carboxylate moiety of E272 in the cyt b Qo ef 
141 helix (this residue is in close proximity to haem bL), causing this sidechain to rotate away from its 
142 inward pointing disposition in the uninhibited enzyme. This is observed with stigmatellin and 
143 NQNO, but not UHDBT [34,36].
144 In contrast to bL-distal inhibitors, bL-proximal inhibitors, such as the natural antibiotics 
145 myxothiazol and strobilurin, and synthetic fungicides such as azoxystrobin characteristically have 
146 hydrogen-bonding interactions with the backbone amide moiety of cyt b residue E272 at Qo (Fig. 
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147 1), with the sidechain of this residue oriented away from the aqueous phase. Often such inhibitors 
148 possess a methoxyacrylate pharmacophore, or derivative of such [34,37]. Generally, bL proximal 
149 inhibitors do not interact with the ISP-ED or affect its mobility, and so this class of compound are 
150 also referred to as 'Pm' (with 'm' indicating that the ISP-ED is mobile, or, at least, not docked at 
151 the IMS-facing surface of the Qo site within cyt b) [34]. 
152 The Qi site, located within cyt b on the opposite side of the IMM to Qo, forms the site of quinone 
153 reduction within cyt bc1. Structurally, it is formed from the C-terminal region of surface helix a, 
154 the N-terminal region of transmembrane helices A and E and the C-terminal regions of helices D 
155 (Fig. 3), and, in contrast to Qo, contains no contributions from the ISP. Cyt bc1 been cocrystallised 
156 with Qi-bound substrate ubiquinone in the chicken, bovine and yeast enzyme, where it is observed 
157 that the benzoquinone moiety forms hydrogen bonds with Qi residues H202 and S206 (yeast 
158 notation) [38-41]. Qi-bound quinone is in close proximity (3.5Å shortest separation) to haem bH, 
159 facilitating rapid electron transfer [12,17]. 
160 Cyt bc1has been cocrystalised with a variety of Qi inhibitors (QiI), such as the natural antibiotics 
161 antimycin A and ascochlorin, and synthetic pyridones [5,10,41-43]. These inhibitors tend to be 
162 structurally diverse molecules, and may not resemble simple variants of benzoquinones, as is often 
163 observed for Qo inhibitors (QoI). Mechanistically, the redox chemistry catalysed at Qi is less 
164 elaborate than that at Qo [9,17], and there is no equivalent of the haem proximal/distal classification 
165 for QiI as observed with QoI. Notably, Qi-inhibition can lead to increased superoxide production 
166 from cyt bc1 due to electron accumulation on the low potential chain (and increased SQo 
167 occupancy) within this enzyme [44-46], which, due to the resulting oxidative stress, may increase 
168 the efficacy of such compounds as antimicrobial agents. It is often overlooked that bL-proximal 
169 QoI (such as myxothiazol) can also stimulate ROS production by cyt bc1, presumably as SQo 
170 generation can still proceed due to dual site occupancy at Qo, allowing one-electron oxidation of 
171 substrate quinol by the ISP (but blocking reduction of cyt b) [47].
172 Finally, we note that some compounds, such as the fungal antibiotic ascochlorin, the synthetic 
173 fungicide ametoctradin and the synthetic antimalarial compound endochin ELQ-400 may act as 
174 dual site Qo/Qi inhibitors [31,32,43]. Such molecules are of particular interest as antimicrobial 
175 agents as cyt b mutation-based resistance is unlikely to develop without significant fitness cost to 
176 the target organism [48].
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177 QoI/QiI binding may result in bathochromic shifts in the visible absorption spectra of reduced 
178 cytochrome bL/bH [37], and this technique is convenient test for the predictions of in silico 
179 modelling approaches. The bL-proximal inhibitors strobilurin and myxoythiazol have been 
180 observed to induce 1-2 nm redshifts of haem bL, shifting the absorption maximum of the α-band 
181 to 566 nm. A similar spectral shift is observed with the bL-distal inhibitor stigmatellin (Fig. 1) [37]. 
182 At Qi, the binding of the antagonist antimycin A induces a 2 nm bathochromic shift in the visible 
183 absorption spectrum of haem bH, shifting the absorption maximum of the α-band to 564 nm.  
184 Relatedly, the phenomenon of 'oxidant-induced reduction' - the reduction of the low potential chain 
185 within cyt bc1 in the presence of QiI and ascorbate or substrate quinol upon addition of an oxidant 
186 such as ferricyanide due to the bifurcated electron transfer chemistry at Qo can also provide clues 
187 as to the mode of action of cyt bc1 Q-site inhibitors [11,49,50]. We recommend the use of these 
188 relatively simple spectrophotometric measurements, which can be performed with crude 
189 membrane preparations, as complementary to in silico binding predictions. Study of the 
190 enzymology of inhibition in Qo/Qi site-directed mutants of yeast (and bacterial) cyt bc1 can also 
191 provide useful information with regards to the mode of action of potential QoI/QiI [1,29,30,51].
192
193 Cytochrome bc1 as a fungicide target in crop phytopathogens
194 Plant disease control is a major issue in agriculture. The fungicide market in Europe, for instance, 
195 represents € 1.8 bn/year; of this, € 1.3 bn/year are for wheat disease control [52]. A wide panel of 
196 fungicides are available with different modes of action and targets, such as the large group of 
197 fungal sterol biosynthesis inhibitors, the growing family of complex II inhibitors, or the cyt bc1 
198 inhibitors. 
199
200 The QoI fungicides and the rapid spread of target site resistance
201 Cyt bc1 is a successful target for agricultural fungicides, with most of the compounds in use being 
202 Qo-site inhibitors (QoIs). They are (and have been) used to control a wide range of plant pathogen 
203 fungi belonging to the ascomycetes, basidiomycetes and oomycetes. Some of the pathogens are 
204 the causative agents of diseases of economically important crops, such as cereals and vines.
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205 The QoIs available on the market include several synthetic strobilurins [53] such as azoxystrobin, 
206 dimoxystrobin, fluoxastrobin, kresoxim-methyl, picoxystrobin, pyraclostrobin, trifloxystrobin, but 
207 also the benzyl-carbamate pyribencarb, the oxazolidine-dione famoxadone and the imidazolone 
208 fenamidone. These compounds are likely to share the same binding mode as the resistance 
209 mutation G143A in the cyt b Qo-site confers cross-resistance to all of these inhibitors. 
210 The first QoI marketed for agricultural use, azoxystrobin, was launched in 1996. Unfortunately, 
211 its efficiency was rapidly challenged within a few years, with, resistant isolates reported in 
212 populations of pathogens, such as Blumeria graminis, (wheat and barley powdery mildew) [54] 
213 and Plasmopara viticola, (grape downy mildew) [55]. We will address additional fungal resistance 
214 mechanisms, namely the upregulation of alternative respiratory pathways and activity of 
215 membrane efflux pumps later in this review.
216 Fungal phytopathogen resistance to azoxystrobin was found to be caused by the cyt b mutation 
217 G143A in the Qo site (Fig. 1, Fig. 3), and, interestingly, A143 is found natively in cyt b of the 
218 strobilurin-producing basidiomycete Mycena galopoda [56]. The G143A substitution has been 
219 now found in isolates from over 25 species of phytopathogenic fungi (see Fungicide Resistance 
220 Action Committee (FRAC): www.frac.info). As such, FRAC often recommend mixing two or 
221 more fungicides with differing modes of action to try and overcome this problem of resistance. 
222 The G143A mutation confers a high level of resistance that can result in a severe loss in disease 
223 control by QoIs. Inspection of the atomic structure of bovine cyt bc1 with bound azoxystrobin 
224 indicates that replacement of G143 by alanine results in a destabilising steric clash with the MOA-
225 bearing phenyl moiety of the fungicide. In yeast, G143A dramatically increases resistance to 
226 azoxystrobin (4,000x) but has no effect on cyt bc1 enzymatic activity [29], indicating that the 
227 binding of substrate ubiquinol is not hindered by the mutation. The high level of resistance without 
228 penalty on the enzyme activity - combined perhaps with a heavy use of QoIs in fields and thus a 
229 strong selection pressure- could explain the rapid emergence and spread of G143A in many fungi. 
230 In some species however, the exon-intron structure of the cyt b gene prevents the appearance of 
231 the G143A mutation [57]. In these species, an intron is located immediately after the codon for 
232 G143. When the G143-encoding codon GGT is located at the exon/intron boundary and is replaced 
233 by codon GCT (encoding alanine) the intron splicing is altered, resulting in a severe decrease in 
234 the amount of mature mRNA. Accordingly, the resulting loss of cyt b due to mutation at this 
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235 mRNA splice junction has been demonstrated in the yeast model [58]. G143A would thus have a 
236 deleterious effect in the intron-containing species, affect the fitness of the resistant cells and be 
237 counter-selected in field.
238 Three other cyt b mutations have been reported in isolates resistant to QoIs – including in the 
239 ‘G143’ intron-containing species. F129L, found for instance in P.viticola and Pyrenophora teres 
240 (Barley net blotch) [59] (and G137R, such as is found for in isolates of Pyrenophora. Tritici-
241 repentis (wheat tan spot) and G137S, found in Venturia effusa (pecan scab) (Fig. 1, Fig. 3) [59,60].
242 G137 is at the N-terminal region of helix cd1, and is close to the interfacial region for ISP-ED 
243 binding. Substitution of glycine by arginine, a bulky and cationic residue is expected to lead to 
244 local distortion of the loop connecting helices C and cd1. In yeast, the mutation causes in a 
245 significant defect in respiratory growth and cytochrome bc1 activity [61]. In pathogenic fungi, the 
246 non-conservative substitution may be expected to result in a fitness penalty, which could explain 
247 the rare occurrence of G137R/S in the field [59,60].
248 The side chain of F129 is oriented toward the hydrophobic cavity that facilitates substrate access 
249 to Qo. The residue is involved in binding the hydrophobic tail of stigmatellin and also presumably 
250 that of ubiquinol [62]. In yeast, the F129L mutation has little effect on the enzyme activity but 
251 decreases its sensitivity to QoIs azoxystrobin and stigmatellin [29]. F129 participates in sidechain 
252 van der Waals associations with these inhibitors in the respective cytochrome bc1 structures, and 
253 the F129L substitution removes stabilising aromatic-aromatic interactions between the protein and 
254 bound azoxystrobin. F129L is not as widely spread in plant pathogen fungi as G143A and confers 
255 a moderate level of resistance. 
256 G143A, now widespread in fungi in the field, is thus a major problem as the mutation confers high 
257 level of resistance and cross-resistance to the whole family of QoIs in use, compromising their 
258 efficiency in disease control.  As such, new compounds are needed that either target the Qi site or 
259 bind at Qo but in a different mode, circumventing G143A-mediated resistance. 
260 Metyltetraprole is a novel QoI that is not affected by the resistance mutation G143A [63]. It is 
261 active against ascomycetes, for instance Zymoseptoria tritici (wheat leaf blotch), a major threat for 
262 wheat production in Western Europe. The compound has side chain similar to that of the synthetic 
263 strobilurin pyraclostrobin, but has a unique tetrazolinone-moiety. It is suggested that this 
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264 tetrazolinone-moiety will not form the same highly specific interactions with the Qo-site as do 
265 other strobilurin-based QoIs and in consequence can accommodate changes in the target, such as 
266 G143A [64]. Thus, the steric clash due to G143A that can compromise the binding of QoIs would 
267 be limited by the unique size and shape of the tetrazolinone. The atomic structure of wt and G143A 
268 cytochrome bc1 with bound metyltetraprole would be needed to confirm its distinct binding 
269 interactions with the target. 
270
271 QiI fungicides in use and under development, and appearance of resistance mutations
272 To date, only three QiI fungicides have been commercialized and are oomycete-specific, namely 
273 the dimethyl-sulfonamides amisulbron and cyazofamid, and the triazolopyrimidine ametoctradin. 
274 In the FRAC repertory of fungicides (www.frac.info), ametoctradin was listed as QoSI i.e. binding 
275 at the Qo-site in a manner similar to stigmatellin but distinct to QoIs [6]. Further spectroscopic 
276 studies indicated that the compound could target both Qo- and Qi- sites [31] and the fungicide was 
277 re-classified as QioI (https://osf.io/qwg42/). However the appearance of the amectotradin 
278 resistance mutation S34L in the Qi-site of P.viticola resistant isolates showed that the fungicide 
279 preferentially target the Qi-site, which was confirmed by the study of the mutation in the yeast 
280 model [51,65]. Analysis of in silico docking of ametoctradin into a homology model of the Qi-site 
281 of P.viticola suggest a binding mode similar to that of ubiquinol in yeast cyt bc1. The aliphatic 
282 octyl- and ethyl substituents of ametoctradin are predicted to form stabilizing hydrophobic 
283 interactions with the sidechains of L17 (helix A), V194 and L198 (C-terminal region of helix D) 
284 (Fig. 3). The interactions between the amino-substituted triazolo-pyrimidinyl headgroup of the 
285 fungicide and the Qi-site appear more hydrophilic, with a putative H-bond with the carboxylate 
286 sidechain of residue D229. A weaker H-bonding interaction between this amino moiety of 
287 ametoctradin and the serinyl sidechain of S34 is also predicted, which would be lost when serine 
288 is replaced by leucine. In addition, the bulky leucine is expected to sterically destabilize the 
289 fungicide binding, which would explain the resistance [31,51]. 
290 A cyazofamid resistance mutation was reported in field isolates of P. viticola. Interestingly, the 
291 mutation is short sequence duplication of six nucleotides resulting in the insertion of two residues 
292 E203-DE-V204 [66], located in the linker region between helices D and E, proximal to the 
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293 benzoquinone headgroup of Qi-site bound quinone in yeast cyt bc1. The insertion is likely to 
294 perturb the local fold around this region, and interfere with cyazofamid access or binding into the 
295 Qi-site. 
296 Fenpicoxamid is a new QiI active against a broad range of ascomycetes, such as the wheat 
297 pathogen Z.tritici . It is still under commercial development. Fenpicoxamid is derived from UK-
298 2A, a natural product of Streptomyces sp. that is structurally related to antimycin [67]. In Z.tritici, 
299 fenpicoxamid is readily converted into UK-2A by removing the isopropylcarboxymethylether 
300 group [68]. UK-2A is 100-fold more potent than fenpicoxamid in inhibiting cyt bc1 [69]. Using 
301 the yeast model, three cytochrome b mutations causing fenpicoxamid resistance were identified, 
302 L198F and G37C and N31K [69]. Notably, mutations of these residues L198, N31 and G37 have 
303 been reported to cause resistance to different Qi-site inhibitors in different organisms. Residue G37, 
304 in particular, seems a hot-spot of resistance mutations [51]. 
305 The binding of UK-2A to yeast cyt bc1 has been modelled in silico [69]. The results suggested a 
306 structural overlap between UK-2A and antimycin A in the Qi binding pocket, with differences, in 
307 particular the pyridine head of UK-2A is flipped by 180 degrees. In this model, the N atom in the 
308 pyridine ring is protonated and can form a salt bridge with the carboxyl group of D229, a key 
309 residue in Qi-site inhibitor binding. However, in contrast to UK-2A, other Qi-site inhibitors form 
310 a hydrogen bond with an O atom of D229. It is likely that the local electrostatic environment 
311 around D229 is affected by the replacement of the nearby residue N31 by lysine (N31K), disrupting 
312 the salt bridge (or bound water molecules, which may also interact with the Qi antagonist [69]) 
313 and in consequence weakening the inhibitor binding. Destabilising steric hindrance is likely to 
314 explain the resistance caused by G37C and L198F, as the substitutions result in bulkier residues.   
315
316 Alternative QoI/QiI resistance mechanisms in fungal phytopathogens 
317 In addition to mutations in the inhibitor binding site within cyt b that account for most of the cases 
318 of reported resistance, other mechanisms may induce resistance towards QoIs and QiIs, such as 
319 increased efflux of fungicides and activation of a mitochondrial alternative oxidase (AOX) [70 -
320 72]. These mechanisms need to be taken into account in the strategies for monitoring and 
321 controlling the development of resistance.
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322 Increased drug efflux is less prevalent and result in lower resistance level than cyt b mutations. It 
323 is caused by the upregulation of membrane transporters. As these efflux pumps can often transport 
324 different compounds, their increased activity lead to multiple drug resistance (MDR). In Z.tritici, 
325 for instance, MDR was reported and found be caused by the overexpression of the transporter 
326 MFS1, induced by insertions in the promoter of its encoding gene [72,73]. 
327 AOX forms an alternative respiratory pathway within the mitochondria of the phytopathogen 
328 which may be upregulated when cyt bc1 is inhibited. AOX is a single-subunit, (non-haem) di-iron 
329 containing monotopic membrane protein which functions as a non-protonmotive quinol oxidase, 
330 which is widespread in plant, fungal and protist mitochondria (but notably absent from the 
331 Plasmodium sp.) [74-76]. The activity of AOX allows ubiquinol-linked respiration from NADH 
332 (via mitochondrial complex I) to oxygen, bypassing the inhibition of cyt bc1, although at much 
333 reduced energetic efficiency. 4 protons may be expected to be pumped into the IMS per 2 electrons 
334 transferred to oxygen in this alternative respiratory pathway due to the activity of protonmotive 
335 complex I alone (i.e. 4H+/2e-) [75]. This represents a significant decrease from the 10H+/2e- yield 
336 expected for cyt bc1/cytochrome c oxidase-linked respiration. Putatively AOX-linked fungicide 
337 resistance was first noted in laboratory-generated strains of Z. tritici, that were resistant to the 
338 (then) newly developed QoI azoxystrobin [77], and has subsequently has been observed in 
339 QoI/QiI-treated field isolates of the phytopathogens P. viticola, Z. tritici, Magnaporthe grisea and 
340 Mycosphaerella fijensis [65,78-80]. In vitro studies suggest that, in the absence of selective 
341 pressure, AOX overexpression in P. viticola sporangia comes with an associated fitness penalty 
342 [6], presumably due to the decreased energetic efficiency of mitochondrial respiration as outlined 
343 above. Accordingly, the fungal preinfection stages of spore germination and host penetration may 
344 be unlikely to develop AOX-associated QoI/QiI resistance due to the ATP demand of these 
345 processes [53,70,77,80]. In vitro, AOX activity can be inhibited by the benzhydroxyamic 
346 compound salicylhydroxamic acid (SHAM), a presumed competitive inhibitor for ubiquinol. 
347 SHAM is a relatively poor inhibitor of the AOX, with an inhibition constant (Ki) of 21 μM against 
348 the Trypanosoma brucei enzyme (as measured by glycerophosphate-linked oxygen uptake assay) 
349 [81]. As an anti-fungal agent, SHAM has also been observed to act synergistically with QoI 
350 inhibitors in vitro, but this response is species (and QoI) dependent [65,70,82]. Unfortunately, 
351 SHAM is a relatively non-specific inhibitor and poorly taken up by plants, and so is unsuitable for 
352 use in the field [70]. It must also be noted that the native AOX activity is important for maintaining 
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353 redox (and metabolite) homeostasis in plants, and inhibition of this enzyme may be deleterious 
354 under osmotic- and light stress conditions [83,84]. Nevertheless, the intriguing possibility exists 
355 of the development of dual fungal cyt bc1/AOX inhibitors, as compounds such as the quinoline 
356 aurachins, produced by the myxobacterium Stigmatella aurantiaca, are inhibitors of both enzymes 
357 [85-88]. We note also the potential for complex I/cyt bc1 inhibition for fungicidal activity as Δp 
358 would be expected to be severely diminished under such circumstances, regardless of the activity 
359 of AOX. Complex I-targeting fungicides are not in widespread use, although the methylpyrimidin-
360 4-amine compound diflumetorim is approved for use in Japan for treatment of rust and powdery 
361 mildew infection of ornamental crops [89]. 
362 The QoI alkoxyimionacetamide fungicide SSF-126 has been reported to increase superoxide 
363 production in M. grisea [90], and although the Qo site of cyt bc1 is the likely source of origin 
364 (presumably SSF-126 is acting as a bL-proximal inhibitor in this instance, or there is cross 
365 reactivity of this compound with Qi), this has not been tested directly. AOX expression was 
366 observed to be strongly induced on treatment with SSF-126, although interestingly the addition of 
367 exogenous hydrogen peroxide was also observed to increase AOX mRNA transcript levels [78]. 
368 Earlier studies reported a possible ROS-associated link with AOX expression in the yeast 
369 Hansenula anomala (syn. Pichia anomala) [91], and more recently, in tomato leaves [92]. The 
370 signalling pathway controlling this mechanism is unknown, but it potentially may be exploited in 
371 the development of future cyt bc1-targeted fungicides (by, for instance, stimulating mitochondrial 
372 catalase or peroxidase expression) to minimise AOX-associated resistance mechanisms.  
373 The significance of phytopathogen AOX activity with regards to QoI/QiI fungicide resistance in 
374 the field has been debated [6,70 ]. Its increasing prevalence, however, warrants close attention, 
375 particularly as this respiratory shunt (and MDR activity, as described above) may facilitate the 
376 development of QoI/QiI-resistant cyt b mutants [65].
377 Finally, we note the potential of the new, bifunctional 'hybrid' antifungal agents under development, 
378 that combine strobilurin- and aromatic amide pharmacophores. Such compounds are thus capable 
379 of targeting both cyt bc1 and succinate dehydrogenase (an additional antipathogenic target). These 
380 hybrid compounds have demonstrated notable efficacy against the plant pathogens Pyricularia 
381 oryzae and Sclerotinia sclerotiorum under laboratory conditions [93]. 
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382
383 Cyt bc1 as a chemotherapeutic target of the human malaria parasite
384 The cytochrome bc1 complex of the human malaria parasite Plasmodium falciparum has a number 
385 of unique features that enable drug selectivity in humans. Notably, a four-residue deletion in the 
386 cd2 helix (Fig. 3) of plasmodial cyt b, a region of the protein in close proximity to key structural 
387 components of the Qo site and the mobile domain of the ISP may modify the conformation of Qo 
388 in the parasite, forming an exploitable element for antagonist selectivity. Sequence differences 
389 between Plasmodia and humans in the C-terminal region of the E-ef loop of cyt b (notably the loss 
390 of histidine and lysine residues in the parasite), a region of the protein adjacent to catalytically 
391 essential ef helix element of Qo, may also help drive drug selectivity [2,94,95].
392
393 Besides contributing to the mitochondrial Δp [76,96-98], the quinol oxidase function of cyt bc1 
394 performs an important role within Plasmodium mitochondria, oxidising the electron acceptor pool 
395 for DHODH-mediated pyrimidine biosynthesis. As noted previously, the mitochondria of 
396 Plasmodium sp. lack the AOX found in plants, fungi and other protists, and so are reliant upon cyt 
397 bc1 activity for this function [76].  During the intraerythrocytic stage of parasite development 
398 within the human host, provision of quinol oxidase function is believed to be essential for parasite 
399 survival.  Consistent with this, inhibition of cyt bc1 results in an increase in carbamoyl-aspartate 
400 and a reduction in UTP, CTP, and dTTP [3,99 -101]. Further evidence of an essential link between 
401 mitochondrial function and pyrimidine biosynthesis is supported by the generation of an 
402 atovaquone-resistant phenotype in transgenic P. falciparum parasites expressing ubiquinone-
403 independent yeast DHODH [102]. Inhibition of Plasmodium cyt bc1 has been shown to affect the 
404 conversion of fumarate to aspartate, further linking mitochondrial function with pyrimidine 
405 biosynthesis and also possibly purine metabolism [103] .
406
407 Inhibition of P. falciparum cyt bc1 during the intraerythrocytic (blood) stages of parasite 
408 development result in a relatively slow death phenotype compared with other antimalarials such 
409 as artemisinin and semisynthetic derivatives thereof [3,104,105]. This feature appears to be 
410 consistent with other mitochondrially-acting antimalarials and is possibly due to the drug acting 
411 only on late trophozoites and not on the earlier ‘ring’ stages [3,106,107]. Inhibition of P. 
412 falciparum cyt bc1 has also been validated against liver stages of the malaria parasite, resulting in 
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413 the utility of any developed inhibitors as prophylactic agents; however, inhibition of the parasite 
414 cyt bc1 is not believed to be active against ‘dormant’ P. vivax/ovale hypnozoites and therefore not 
415 suitable for potential radical cure of relapse malaria [108,109].
416
417 Development and pharmacology of the cyt bc1 Qo inhibitor atovaquone
418 Atovaquone (Fig. 4) is the prototypal inhibitor of the Plasmodium cyt bc1 that was successfully 
419 developed and registered for clinical use [110].  Currently, atovaquone is used as a fixed-dose 
420 combination with proguanil (Malarone) for the treatment of children and adults with 
421 uncomplicated malaria or as a chemoprophylactic agent for preventing malaria in travellers [108 
422 ,111].  In recent years in the USA, Malarone has been estimated to account for ca.70% of all 
423 antimalarial pre-travel prescriptions [112].  Atovaquone is the product of over 50 years of research-
424 intensive efforts to develop a safe and effective antimalarial [110].  Much of what is known of the 
425 essentiality of the parasite cyt bc1 target and the physiological role of cyt bc1 in mitochondrial 
426 function and linked biosynthetic pathways e.g. pyrimidine pathway (see section 3.0), is through 
427 the use of atovaquone.
428
429 Atovaquone binding to cyt b was initially hypothesised based on studies performed on model 
430 organisms and molecular modelling. These studies, which include electron paramagnetic 
431 resonance spectroscopy of the Rieske [2Fe2S] cluster, site-directed mutagenesis of model 
432 organism cyt b and gene sequencing of atovaquone-resistant Plasmodium species, demonstrate 
433 that atovaquone is most likely a competitive inhibitor of the parasite's cyt b Qo site [1,2].  These 
434 studies were further supported by the demonstration using the X-ray structure of mitochondrial cyt 
435 bc1 from S. cerevisiae, of atovaquone bound in the bL-distal region of the Qo site, at 3.0-Å 
436 resolution [4].  This study again confirmed the critical role of a polarized H-bond to His181 of the 
437 extrinsic domain of the Rieske protein that interacts with the ionized hydroxyl group of the drug. 
438 The sidechain of PEWY-residue Y279 (Fig. 1, Fig. 3) provides an important (and orienting) 
439 aromatic-aromatic interaction with the hydroxynaphthoquinone moiety of the drug, stabilising its 
440 binding within Qo. The carbonyl groups of the Qo-bound atovaquone molecule do not appear to be 
441 directly involved in H-bonding associations with the polypeptide backbone of cyt b, with the 
442 glutamyl sidechain of E272 pointing away from the drug, and towards haem bL, in a manner 
443 reminiscent of that for the interaction with HDBT [36].
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444
445 Malarone drug failure has been associated with atovaquone resistance, specifically with a missense 
446 point mutation at position 279 in cyt b (yeast notation, corresponding to 268 in the P. falciparum 
447 protein sequence), exchanging tyrosine for serine or cysteine (Y279S/C) or, less frequently, 
448 asparagine (Y279N) [1,113-117]
449
450 Position 279 in cyt b is highly conserved across all phyla and is located within the ‘ef’ helix 
451 component of the Qo site (Fig. 1, Fig. 3), which is putatively involved in ubiquinol binding. The 
452 resultant atovaquone-resistant growth IC50 (half-maximal inhibitory concentration) phenotype of 
453 these mutants is some 1000-fold higher than susceptible strains; however, this is accompanied by 
454 a ∼40% reduction in the Vmax of cyt bc1, suggestive of a significant fitness cost to the parasite [48]. 
455 We note that the Y279S mutation in P. falciparum confers weak cross-resistance to Qo bL-proximal 
456 inhibitor myxothiazol in vitro [48] (although this naturally-occurring antibiotic is unsuitable for 
457 use as an antimalarial agent). Interestingly, the G143A resistance mutation, as discussed earlier, 
458 and so prevalent in fungal phytopathogens, has yet to be observed in laboratory or field isolates of 
459 this organism.
460
461 Atovaquone monotherapy gives rise to de novo resistance very rapidly [118,119]. The underlying 
462 reason for this phenomenon has not been determined but pharmacodynamic/pharmacokinetic 
463 considerations as well as the multiple copy number of mtDNA (ca. 30 in P. falciparum and up to 
464 150 in P. yoelli  [120]) and the effect of an increased mutation rate of mitochondrially encoded 
465 genes have been discussed as potential contributing factors[110].  Whilst de novo resistance to 
466 atovaquone can occur rapidly in the blood stages of P. falciparum, malaria transmission studies 
467 suggests that resistant parasites harbouring specific cyt b mutations are not able to complete their 
468 development in the mosquito and are therefore unlikely to spread in the field [121].
469
470 A further notable recent development has been in the formulation of atovaquone slow-release 
471 strategies for chemoprotection. In rodent malaria models, atovaquone solid drug nanoparticles 
472 have been demonstrated to confers long-lived prophylaxis against malaria [122]. Pharmacokinetic-
473 pharmacodynamic analysis indicates that if translated to humans this could potentially result in 
474 protection for at least one month after a single administration. 
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475
476 Development of second-generation P. falciparum cyt bc1 inhibitors: pyridones, 
477 acridinediones, acridones and quinolones
478 Whilst the development of atovaquone gave rise to a new antimalarial therapy, its sub-optimal 
479 efficacy when used for malaria treatment (versus prophylaxis), the cost and complexity of 
480 synthesis resulting in a high cost of goods, as well as the observed rapid emergence of parasite 
481 resistance, limited its potential use for the treatment of patients in malaria endemic settings [110].  
482 However, the malaria parasite cyt bc1 offered a rare opportunity to drug developers as one of the 
483 few known validated drug targets resulting in the development of several inhibitor chemotypes.
484
485 Pyridones have been shown to possess antimalarial activity since the 1960’s with the 
486 demonstration that clopidol possessed antimalarial efficacy against chloroquine resistant parasites 
487 [2].  In the early 2000’s, GSK Pharmaceuticals reported the pre-clinical development of pyridones 
488 targeting cyt bc1 of P. falciparum displaying activity against atovaquone-resistant parasites [123].  
489 Development of pyridones by GSK containing an atovaquone-like bicyclic side chain gave rise to 
490 a clinical candidate GSK932121 (Fig. 4) which entered Phase 1 clinical trials in 2008[124]. 
491 However the trial was suspended due to the concurrent discovery of cardiotoxicity in animal 
492 studies dosed with the phosphate ester of the drug [125].  The toxicity was attributed to higher 
493 systemic exposure of the parent drug which was later confirmed when similar toxicity was 
494 observed in rats dosed with the parent drug by the intraperitoneal route.  A subsequent study in 
495 which bovine cyt bc1 was co-crystallised with the GSK932121 and other 4(1H)-pyridone class of 
496 inhibitors, demonstrated that these inhibitors do not bind at the Qo site but bind at the Qi site, 
497 thereby providing an explanation for the apparent activity against atovaquone-resistant parasites 
498 (harbouring Qo-site mutations) [5]. However, the study also demonstrated a much lower 
499 therapeutic index of the pyridones against bovine cyt bc1 compared to atovaquone, thereby also 
500 providing a molecular explanation for the cardiotoxicity and eventual failure of GSK932121 in the 
501 phase-1 clinical trial.  
502
503 Nevertheless, the Qi site of P. falciparum cyt bc1 offers itself as a promising target for drug 
504 development, particularly in combination with a Qo-directed antagonist, such as atovaquone. We 
505 present a protein sequence alignment of the cyt b Qi site from P. falciparum in comparison with 
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506 yeast and selected vertebrates in Fig. 5. This figure also highlights residues in the atomic structure 
507 of bovine cyt b (PDB accessions 1NTK, 4D6T and 4D6U in hydrogen-bonding or hydrophobic 
508 (sidechain/ligand) interaction with antimycin and the 4(1H)-pyridone-class inhibitors GW844520 
509 and GSK932121 [5,35]. The N-terminal region of transmembrane helix E within P. falciparum cyt 
510 b Qi appears to offer considerable sequence diversity compared to mammalian counterparts, which 
511 may form exploitable differences for drug development. In particular, we highlight the single 
512 residue deletion in the loop connecting helices D and E, and the presence of aliphatic- for ionic 
513 sidechain substitutions at L206, L217 and K220 (P. falciparum notation) for aspartate, lysine and 
514 leucine respectively in the human sequence data at the N-terminus of transmembrane helix E. 
515 Y211/N213 in the parasite sequence in the same region also appear to offer significant steric (and 
516 electrostatic) diversity from the His/Tyr dyad at the equivalent position in the human sequence. 
517 Given the considerable challenge of obtaining an atomic structure for P. falciparum cyt bc1, it is 
518 likely that yeast cyt b side-directed mutants may provide suitable surrogates for the study of 
519 antagonist binding at Qi. 
520
521 Drugs based on the acridine chemotype have a long history in malaria chemotherapy, indeed 
522 mepacrine was the first synthetic antimalarial blood schizontocide used clinically [126] and the 
523 related drug pyronaridine is still in use today in the form of Pyramax (pyronaridine-artesunate 
524 combination).  Additional acridine derivatives include the acridones and the dihydroacridinediones, 
525 all of which display potent antimalarial activity e.g. [127]  Whilst the antimalarial efficacy of 
526 acridine congeners has been shown to derive from their ability to bind haem and thereby interfere 
527 with the parasite process of haem crystallisation [94,128-132],some potent dihydroacridinediones 
528 and acridones have been demonstrated to inhibit malaria parasite O2-consumption  [133]and 
529 specifically inhibit parasite cyt bc1 [94,127] .  Experiments performed with yeast manifesting 
530 mutations in cyt bc1 reveal that binding of dihydroacridinediones is directed to the quinol oxidation 
531 site (Qo) of cyt bc1 [94]. 
532
533 Quinolones have been studied extensively as bc1-targeting antimalarials [2,95,134].  A 
534 comprehensive set of alkyl- and alkoxy 4(1H)-quinolones have been synthesised in an effort to 
535 determine the structure activity relationship (SAR) for antimalarial efficacy against asexual P. 
536 falciparum parasites, including atovaquone-resistant lines [135]. This work led to the discovery of 
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537 ELQ-300 and P4Q-391 which were eventually selected as the preclinical candidate and backup 
538 molecule respectively, by the Medicines for Malaria Venture (MMV) [136].  ELQ300 and P4Q-
539 391 (Fig. 4) were developed based on endochin, which was discovered over 70 years ago [137].  
540 However whilst endochin and related alkyl-4(1H)quinolones possess antimalarial efficacy, the 
541 barrier to development was the metabolic instability due to the long alkyl chain. Replacement of 
542 the alkyl chain by the side chain from the previously described GSK pyridone series [124] proved 
543 to be a breakthrough for this chemotype as the molecules demonstrated improved metabolic 
544 stability while retaining antimalarial efficacy. Crucially ELQ300 displays improved selectivity 
545 over human cyt bc1 relative to the withdrawn pyridone series [136].  Inhibition of the parasite cyt 
546 bc1 is believed to be at the Qi site (Fig. 5) [5], probably as a consequence of the QSAR being 
547 directed against atovaquone-resistant parasites harbouring Qo-site mutations.  Interestingly, in 
548 vitro isobole analysis of atovaquone and ELQ300 combination efficacy displays a synergistic 
549 interaction, suggesting that Qo and Qi inhibitors are a favourable combination strategy.  
550
551 As outlined earlier, dual-site resistance may be expected to be unlikely to develop due to the 
552 increased probability of an associated organismal fitness penalty [48]. Additionally, inhibition at 
553 Qi is likely to lead to increased (superoxide-linked) oxidative stress within the pathogenic 
554 organism [46]. (We also note that putative dual P. falciparum cyt bc1/NADH dehydrogenase 
555 inhibitors, such as the quinolone lead compound SL-2-25 [3] may also increase oxidative stress 
556 within the pathogen due to dehydrogenase-associated flavosemiquinone formation [138]. In 
557 addition, the Qo-Y279S mutation does not confer appreciable resistance to this compound, nor to 
558 the related compound CK-2-68 [3,139]).
559
560 The ELQ class however does have some limitations, most notably the class suffers from poor 
561 aqueous solubility which in vivo is reflected in limited absorption and bioavailability – whilst this 
562 is not an issue in terms of reaching adequate in vivo exposures for efficacy, it is not possible to 
563 establish maximum tolerated doses to establish a therapeutic index.  This issue stalled ELQ-300 
564 development. However more recently prodrug approaches are attempting to overcome this issue.  
565 ELQ-331, an alkoxycarbonate ester of ELQ-300, is currently the lead prodrug that is reported to 
566 have significantly increased ELQ-300 exposure after oral dosing [140]. ELQ-331 is currently 
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567 advancing pre-clinical development as an oral formulation and is also being progressed as a long-
568 acting injectable chemoprotection agent [141]. 
569
570 Other notable quinolone-based cyt bc1 inhibitors developments include the identification of 
571 decoquinate [142] and quinolone esters [143], these projects have thus far not developed further 
572 as they have not demonstrated superiority over existing molecules under development described 
573 above.  
574
575 Cyt bc1 as an antipathogenic target - general outlook and future prospects
576 The above discussion about atovaquone makes it clear that the development of parasite resistance 
577 is a concern for the continuing efficacy of cyt bc1 Qo-targeted antimalarial agents. However, this 
578 problem does not seem insurmountable, given the potential for the dual-site (Qo/Qi) combination 
579 therapy, or indeed, the development of true dual-site inhibitors, as proposed for the mode of action 
580 of the endochin compound ELQ-400 in yeast models of P. falciparum cyt bc1 [32]. Furthermore, 
581 the lack of cross resistance to lead compounds such as quinolone Qo-antagonist CK-2-68 in the 
582 atovaquone-resistant P. falciparum strain TM90C2B [3] offers hope for the future exploitation of 
583 the Qo site as an antimalarial chemotherapeutic target
584
585 With regards to fungal phytopathogens the question of QoI/QiI efficacy is even more pressing, in 
586 light of the additional issues of the inducible AOX-mediated respiratory bypass and MDR efflux 
587 pumps. Nevertheless, and as with human malaria parasite, the development of novel fungicidal 
588 QoI/QiI continues, particularly with the example set by the new QiI for treatment of Ascomycete 
589 plant pathogens, fenpicoxamid [69], insensitive to G143A-mediated resistance. As above, dual-
590 site (Qo/Qi) fungicidal activity would seem to offer the best chances against developing viable 
591 resistant strains, particularly if the issue of G143A resistance can be bypassed by the development 
592 of non-strobilurin based inhibitors, occupying the bL-distal region of Qo. The recent exciting 
593 development of 'hybrid' bi-functional fungicides also deserves close observation [93]. Finally, we 
594 note that in the absence of suitable AOX inhibitors, the spread of respiratory bypass-based 
595 inhibition must be carefully monitored, and the necessity of the energetic role played by AOX 
596 during the various developmental stages of fungal growth.  
597
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1003 Cartoon representation of the atomic structure of cyt b (green) and the ISP (orange) of yeast cyt 
1004 bc1 (1EZV.PDB, [39]) with stigmatellin (Stg, pink) bound at Qo. The ISP [2Fe2S] cluster, cyt b 
1005 haems (red)- and sidechains of interest as discussed in the text are represented in wireframe form.
1006
1007 Figure 2
1008 Schematic sketch of the electron- and proton transfer pathways of the cyt bc1 Q-cycle. Cyt b is 
1009 represented in light grey, with the Qo/Qi-pockets in dark grey. 'Red' and 'ox' refer to the reduced 
1010 and oxidised states of the various redox carriers. The positive and negative sides of the energised 
1011 inner mitochondrial membrane are indicated accordingly. 
1012
1013 Figure 3
1014 Cartoon of the secondary structure and membrane disposition of cyt b, displaying the location of 
1015 Qo (red) and Qi (blue) residues of interest (S. cerevisiae notation) as discussed in the text. 
1016 Transmembrane- and surface helices are identified in upper and lower case, respectively. 'n' and 
1017 'p' refer to the negative and positive sides of the energised inner mitochondrial membrane.
1018
1019 Figure 4
1020 Structures of selected anti-malarial compounds in use and under development discussed in the text.
1021
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1022 Figure 5
1023 Protein sequence alignment of the Qi-site region of cytochrome b from P. falciparum (Pf, 
1024 UniProtKB accession: Q02768), S. cerevisiae (Sc, P00163), Gallus gallus (chicken, Gg, P18946), 
1025 Homo sapiens (Hs, P00156) and Bos taurus (cow, Bt, PB00157). Sequence conservation in the 
1026 aligned sequences is indicated using the Clustal Omega convention [144], with asterisks, colons 
1027 and periods indicating complete conservation, conservative substitutions and semi-conservative 
1028 substitutions, respectively. Sequence data were obtained from the UniProt database. Arrows 
1029 underneath the alignment indicate α-helices as identified in Fig. 3. Residues in the bovine 
1030 cytochrome b atomic structures 1NTK [35], 4D6T [5] and 4D6U (ibid) in potential hydrogen-
1031 bonding association with bound antimycin, and the 4(1H)-pyridones GW844520 and GSK932121 
1032 are indicated by red, blue and green circles, respectively. Residues forming stabilising hydrophobic 
1033 contacts with bound GW844520 in the bovine 4D6T structure are shaded in yellow. (GSK932121 
1034 displays similar binding interactions). Protein-ligand associations indicated in this figure were 
1035 predicted- and analysed using the LPC software package [145].
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Figure 1 / Cartoon representation of the atomic structure of cyt b (green) and the ISP (orange) of yeast cyt 
bc1 (1EZV.PDB [39]) with stigmatellin (SMA, pink) bound at Qo. The ISP [2Fe2S] cluster, cyt b haems 
(red)- and sidechains of interest as discussed in the text are represented in wireframe form. 
109x101mm (300 x 300 DPI) 
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Figure 2 / Schematic sketch of the electron- and proton transfer pathways of the cyt bc1 Q-cycle. Cyt b is 
represented in light grey, with the Qo/Qi-pockets in dark grey. 'Red' and 'ox' refer to the reduced and 
oxidised states of the various redox carriers. The positive and negative sides of the energised inner 
mitochondrial membrane are indicated accordingly. 
102x129mm (300 x 300 DPI) 
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Figure 3 / Cartoon of the secondary structure and membrane disposition of cyt b, displaying the location of 
Qo (red) and Qi (blue) residues of interest (S. cerevisiae notation) as discussed in the text. 
Transmembrane- and surface helices are identified in upper and lower case, respectively. 'n' and 'p' refer to 
the negative and positive sides of the energised inner mitochondrial membrane. 
139x106mm (300 x 300 DPI) 
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Figure 4 / Structures of selected anti-malarial compounds in use- and under development as discussed in 
the text. 
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Figure 5 / Protein sequence alignment of the Qi-site region of cytochrome b from P. falciparum (Pf, 
UniProtKB accession: Q02768), S. cerevisiae (Sc, P00163), Gallus gallus (chicken, Gg, P18946), Homo 
sapiens (Hs, P00156) and Bos taurus (cow, Bt, PB00157). Sequence conservation in the aligned sequence 
data is indicated using the Clustal Omega convention [144] , with asterisks, colons and periods indictating 
complete conservation, conservative substitutions and semi-conservative substitutions respectively. 
Sequence data were obtained from the UniProt database. Arrows underneath the alignment indicate α-
helices as identified in Fig. 3. Residues in the bovine cytochrome b atomic structures 1NTK [35], 4D6T [5] 
and 4D6U (ibid) in potential hydrogen-bonding association with bound antimycin, and the 4(1H)-pyridones 
GW844520 and GSK932121 are indicated by red, blue and green circles respectively. Residues forming 
stabilising hydrophobic contacts with bound GW844520 in the bovine 4D6T structure are shaded in yellow. 
(GSK932121 displays similar binding interactions). Protein-ligand associations indicated in this figure were 
predicted- and analysed using the LPC software package [145]. 
149x104mm (300 x 300 DPI) 
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